SAN ANTONIO — Nice try, ATEMPT investigators, but trastuzumab emtansine (T-DM1) does not have a disease-free survival or safety advantage over paclitaxel plus trastuzumab in the adjuvant setting for ...

Earlier this week, it was announced that survival data are in for T-DM1, an experimental breast cancer drug for HER2-positive breast cancer, and the results are positive. We just don't know how ...

In news that is bound to excite breast cancer patients and investors, Genentech/Roche/Immunogen issued press releases on August 26, 2012, confirming that their drug-of-the-moment T-DM1 (trastuzumab ...

Patient undergoing chemotherapy. Trastuzumab deruxtecan improves overall survival vs trastuzumab emtansine in previously treated, HER2-positive, advanced breast cancer, a phase 3 trial suggests.

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive ...

Sara Hurvitz, MD, FACP, shares insights into the results of the HER2CLIMB-02 trial, which saw patients with HER2-positive breast cancer benefit from the addition of tucatinib to trastuzumab emtansine ...

The treatment of metastatic HER2-positive breast cancer is evolving rapidly with the development of effective targeted therapies. Investigators from 22 countries participated in the TH3RESA study, a ...

T-DM1 is also in Phase III trials in women with newly diagnosed and previously treated breast cancer. And trials in earlier-stage disease are also planned, which will expand the market for the drug.

just disclosed partial results from the pivotal study of T-DM1 in third-line breast cancer patients that’s to be presented at a medical meeting on Saturday. The objective response rate in the study ...

Let's Not Throw the Baby out With the Bathwater in Prostate Cancer Screening In the article that accompanies this editorial, Dzimitrowicz et al 10 provide a real-world glimpse of T-DM1 in patients who ...